The longevity field is challenging traditional disease-based regulatory frameworks. At a landmark meeting convened by the Reagan-Udall Foundation for the FDA in May, co-sponsored by ARPA-H's PROSPR program and the XPRIZE Foundation, the industry's most stubborn bottleneck was addressed: the regulatory impasse caused by defining aging as a disease. As reported by Longevity Technology, the summit explored innovative approaches such as functional metrics and pragmatic stepping-stone indications to accelerate approval for therapies that slow or reverse aging. Traditional disease models are ill-suited for multifactorial processes like aging. By using biomarkers and quality-of-life measures as functional outcomes, regulators can better evaluate progress in this field. Nordic countries, with their integrated health systems, are leading in incorporating longevity research into public health. These developments could reshape regulatory frameworks globally, providing a clear pathway for testing and approving anti-aging treatments. The meeting signals a shift toward more flexible, outcome-based regulation that could unlock the potential of regenerative medicine.